Overview
Navigating the complexities of product liability litigation can be daunting for pharmaceutical and medical device manufacturers. Because of the sector’s stringent regulations and high stakes, securing tenacious, industry-savvy legal representation to protect your interests is not just a recommendation, it's a necessity.
This is why pharmaceutical and medical device manufacturers turn to Epstein Becker Green's Drug and Medical Device Litigation Group. Our seasoned lawyers possess extensive experience litigating product liability matters unique to these manufacturers.
An Industry-Specific Strategy
Every product liability matter presents its own challenges. How a company responds to those challenges is a function of its business model and the nature of its industry.
Epstein Becker Green's Drug and Medical Device Litigation Group seeks to become keenly aware of your company's specific business goals, needs, and economics and the impact of potential liability on your company. The group uses the resources of Epstein Becker Green's Health Care and Life Sciences practice, which has a special focus on the pharmaceutical and medical device industries, and the firm's Litigation & Business Disputes practice to help your company manage risk. We represent pharmaceutical and medical device manufacturers not only in product liability matters but also in a wide range of civil and criminal matters, including class actions and government investigations.
Litigation Avoidance
Epstein Becker Green does not accept the premise that the role of the lawyer is simply to react to bad events—such as the filing of a lawsuit against a client. Rather, an integral aspect of the Drug and Medical Device Litigation Group is to take proactive measures through direct interface with clients to avoid lawsuits in the first place. Many of the most important decisions to minimize risk and exposure are often made before the company is a litigation target.
Pharmaceutical and medical device manufacturers address a significant number of regulatory requirements associated with the research, development, pricing, promotion, marketing, and selling of medical devices and ethical drugs. As scrutiny on the pharmaceutical and medical device industries from the public, federal and state regulators, and enforcement agencies continues, companies operating in these industries must remain even more vigilant and knowledgeable about the regulatory parameters that affect them. Members of the Drug and Medical Device Litigation Group, in conjunction with our health care regulatory lawyers in the FDA Inspections and Enforcement Group, provide comprehensive legal services relating to all aspects of product development, the FDA regulatory approval process, label development, and post-approval marketing and advertising. We provide FDA counseling to manufacturers relating to promotional matters and off-label distribution issues. We provide counseling with regard to all aspects of post-market clinical trial research programs and grant administration. The regulatory areas in which we counsel our pharmaceutical and medical device clients often are crucial to the defense of product liability litigation.
The Medicine
Epstein Becker Green lawyers have extensive experience litigating cases that require a thorough knowledge of epidemiology, toxicology, and medical sciences. In deposition and at trial, we demonstrate a firm grasp of the scientific and medical issues critical to the defense of the case. We routinely use Daubert and Frye hearings to attack the credibility of adversarial experts and limit the effectiveness of those experts in court.
The Courtroom
Epstein Becker Green aggressively defends its clients in product liability litigation in state and federal courts throughout the United States. Members of the Drug and Medical Device Litigation Group are seasoned trial lawyers who bring a combination of extensive preparation and creativity to the courtroom. While we strive to prevail by summary judgment where possible, we have no qualms about trying jury cases to verdict.
Complex, Class Actions, and Multi-District Litigation
Epstein Becker Green lawyers represent companies in both federal and state class actions, multi-district litigation, and mass actions. Our clients' first (and often best) opportunity to successfully defend a class action is to defeat certification of the putative class or prevent the amassing of dissimilar claims. We have been victorious in opposing class certification and claims aggregation for many clients across many industries through thoughtful and comprehensive pre-certification discovery and investigation, coupled with the development of creative, case-specific strategies.
Crisis Management
Because of the potentially significant impact of product liability claims on a company's reputation, we also assist our clients with developing legally and operationally sound internal and public communications throughout the discovery, management, and resolution of adverse events.
Read less
Focus Areas
Services
Experience
Contacts
- Member of the Firm
- Member of the Firm
Media
Events
Past Events
- November 3, 2022
- May 12, 2022
- September 28, 2021
Insights
Insights
- Media CoverageBradley Merrill Thompson Quoted in “Convergence: Experts Offer Advice on Leveraging AI in Regulatory”3 minute read
- Firm Announcements
Epstein Becker Green Earns Finalist Spots in New Jersey Law Journal's 2024 Legal Awards: Celebrating Excellence in ...
4 minute read - BlogsRecent Supreme Court Decisions and the DSCSA15 minute read
- PublicationsFTC Releases Controversial Interim Staff Report on PBMs’ Purported Impact on Drug Prices3 minute read
- BlogsFDA Guidance on DSCSA Small Dispenser Exemption and Exemptions and Waivers for Other Trading Partners13 minute read
- Media CoverageBradley Merrill Thompson Cited in “AI Regulation: Global Picture Balances Innovation and Insight”3 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Experts Advise Against Prescriptive FDA Policies for Regulating AI”3 minute read
- Media CoverageJames Boiani Quoted in “Jazz Pharma to Fight FDA in Court Over Rival Sleep Drug Approval”5 minute read
- Media CoverageTheodora McCormick Quoted in “‘Vague’ NY Law Looms for the Vitamin Shoppe, Other Supplement Retailers”3 minute read
- Media CoverageTeddy McCormick Quoted in “NPA to Seek Injunction Against NY Law Related to Weight Loss Supplements”4 minute read
- Media CoverageMaximilian Cadmus and William Gibson Featured in “New Partners Yearbook 2024”2 minute read
- Media CoverageJames Boiani Quoted in “Clinical Lab Consolidation Continues in 2023 While Key Policy Questions Go Unresolved” ...2 minute read
- Media CoverageJames Boiani Quoted in “FDA Braces for High Court, Final Rule Moves in Election Year”3 minute read
- Firm AnnouncementsEpstein Becker Green Announces 2024 Promotions6 minute read
- Publications
Checking In on How SuperValu Has Altered FCA Litigation
4 minute read - PublicationsDietary Supplement Makers Face "Misbranding" Minefield, Need FDA Guidance7 minute read
- Media CoverageBradley Merrill Thompson and the CDS Coalition Request FDA Rescind Final Decision Support Guidance2 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Why Congress Quietly Just Gave the FDA More Power”3 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Industry Group Petitions FDA to Withdraw CDS Guidance”5 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Software to Predict Risk of Sepsis, Stroke Should Be Regulated as a Medical Device ...4 minute read
- Media CoverageBradley Merrill Thompson Quoted in “FDA’s Tweak of Mobile Medical Apps Guidance Introduces Transparency ...2 minute read
- Media CoverageBradley Merrill Thompson Quoted in “FDA Lays Out CDS Stance”1 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Legal Expert: FDA’s CDS Software Guidance Is a ‘Disaster’ for Industry” ...3 minute read
- Media CoverageBradley Merrill Thompson Quoted in “FDA Finalizes Guidance on How Clinical Decision Support Software Is Regulated” ...2 minute read
- Media Coverage
Bradley Merrill Thompson Featured in BioWorld: Discussion of FDA Guidance for CDS Software
1 minute read - Media CoverageBradley Merrill Thompson Quoted in “FDA Guidance Hikes Oversight of Clinical Decision Support Software”3 minute read
- Media CoverageBradley Merrill Thompson Quoted in “FDA Talks Takeaways from Software Precert Pilot”2 minute read
- Media CoverageEpstein Becker Green’s Unpacking Averages Report “Casts Doubt on Value of US FDA’s Breakthrough Devices Program” ...2 minute read
- Firm AnnouncementsEpstein Becker Green’s Theodora McCormick Recognized as a Trailblazing Change-Maker by the Executive Women of New Jersey ...4 minute read
- PublicationsPrescription Digital Therapeutics Don't Need a Physician3 minute read
- Media CoverageTheodora McCormick Quoted in “The Top Product Liability Cases of 2021”2 minute read
- Firm Announcements
Epstein Becker Green Launches Commercial Litigation Update Blog to Highlight Litigation Concerns for Businesses and ...
3 minute read - PublicationsAntitrust Law Compliance During Public Health Emergencies2 minute read
- Firm Announcements
Corporate Counsel Rank Epstein Becker Green as "Litigation Standout" in BTI Litigation Outlook 2020 Report
2 minute read - Media CoverageBradley Merrill Thompson Quoted in "Device Lawyer: FDA's Pre-Cert Update Seems Promotional, Lacks Answers"3 minute read
- Media CoverageJames Boiani Quoted in "What's Next for the Post-Gottlieb FDA"3 minute read
- Media CoverageStuart Gerson Quoted in "Drug, Device Lobbies Weigh In on Utah Device Liability Case"1 minute read
- Media CoverageStuart Gerson Quoted in "Pharma Charity's Suit Tests OIG's Kickback Oversight"2 minute read
- Media CoverageBradley Merrill Thompson Quoted in "Don't Wait for the Apple Watch to Dole Out Medical Advice Anytime Soon"2 minute read
- Media CoverageBradley Merrill Thompson Quoted in "Reject Off-Label Drug, Device Promotion Bills, Groups Tell Lawmakers"2 minute read
- Media CoverageBradley Merrill Thompson Quoted in "Senators Want to Fix FDA's Inspection Process for Device Companies"2 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Include Risk Tolerance Info in Device Approval Requests: FDA”1 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Medical Software Group Presses FDA for Regulatory Clarity”2 minute read